Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
3D MedicinesHKSE:01244 -4.63%47 PS Ratio is 1.42 as of Sep. 14, 2026, which is 31% below its 10-year median of 2.06. GuruFocus rates HKSE:01244 with a GF Score™ of 47/100 and a GF Value™ of HK$3.09 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 940 Biotechnology companies, 3D Medicines ranks better than 88.83% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, 3D Medicines's share price is HK$2.265.
3D Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1.59. Hence, 3D Medicines's PS Ratio for today is 1.42.
The historical rank and industry rank for 3D Medicines's PS Ratio or its related term are showing as below:
HKSE:01244'
s PS Ratio Range Over the Past 10 Years
Min: 0.52 Med: 2.06 Max: 147.06
Current: 1.42
During the past 6 years, 3D Medicines's highest PS Ratio was 147.06. The lowest was 0.52. And the median was 2.06.
HKSE:01244's PS Ratio is ranked better than 88.83% of 940
companies
in the Biotechnology industry
Industry Median: 9.33
vs HKSE:01244: 1.42
3D Medicines Inc revenue per share has been in decline over the past 3 years.
During the past 12 months, the average Revenue per Share Growth Rate of 3D Medicines was -17.50% per year.
During the past 3 years, the average Revenue per Share Growth Rate was -51.40% per year.
During the past 6 years, 3D Medicines's highest 3-Year average Revenue per Share Growth Rate was 88.70% per year. The lowest was -51.40% per year. And the median was 18.65% per year.
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
3D Medicines PS Ratio Related Terms
3D Medicines PS Ratio Historical Data
* Premium members only.
The historical data trend for 3D Medicines's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:01244 vs VRTX, REGN, MRNA: PS Ratio Comparison
For the Biotechnology subindustry, 3D Medicines's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
3D Medicines PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 3D Medicines's PS Ratio distribution charts can be found below:
* The bar in red indicates where 3D Medicines's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
3D Medicines's PS Ratio for today is calculated as
3D Medicines's Share Price of today is HK$2.265.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. 3D Medicines's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$1.59.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
3D Medicines (HKSE:01244) has a PS Ratio of 1.42 as of Sep. 14, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on 3D Medicines and its competitors. This is 31% below median its historical median of 2.06. Over the past decade, 3D Medicines' PS Ratio has ranged from 0.52 to 147.06. According to the industry distribution chart, 3D Medicines ranks #105 out of 940 companies in the Biotechnology industry, placing it in the top 11.2%.
Is 3D Medicines' PS Ratio too high?
3D Medicines' current PS Ratio of 1.42 is 31% below median its 10-year median of 2.06. Over the past 10 years, this metric has ranged from a low of 0.52 to a high of 147.06. The Biotechnology industry median PS Ratio is 9.33. 3D Medicines' value of 1.42 is 84.8% below this industry median. Based on the distribution chart, 3D Medicines ranks #105 out of 940 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, 3D Medicines has a GF Score™ of 47/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does 3D Medicines' PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, 3D Medicines ranks #105 out of 940 companies for PS Ratio. This places 3D Medicines in the top 11% of its industry — outperforming the majority of peers. The industry median PS Ratio is 9.33. 3D Medicines' value of 1.42 is 84.8% below this benchmark. Historically, 3D Medicines' own PS Ratio has ranged from 0.52 to 147.06 over the past decade. While the company's 10-year median is 2.06 vs. the industry median of 9.33, 3D Medicines has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.33, based on 940 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 3D Medicines's current PS Ratio of 1.42 is 84.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on 3D Medicines and its competitors. For the Biotechnology industry, the median PS Ratio is 9.33 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 3D Medicines's current PS Ratio is 1.42, which is 31% below median its own 10-year median of 2.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 3D Medicines stock overvalued right now?
Based on GuruFocus' analysis, 3D Medicines (HKSE:01244) is currently considered Modestly Undervalued. The stock's GF Value™ is HK$3.09, compared to a current price of HK$2.27 — trading 26.7% below its estimated fair value. The current PS Ratio is 1.42, which is 31% below median its 10-year median of 2.06 and 84.8% below the Biotechnology industry median of 9.33. 3D Medicines' overall GF Score™ is 47/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For 3D Medicines (HKSE:01244), the current PS Ratio is 1.42 as of Sep. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 3D Medicines (HKSE:01244) Overvalued in 2026?
Based on GuruFocus' analysis, 3D Medicines stock appears to be undervalued.
The current stock price of HK$2.27 is trading 26.7% below its estimated GF Value™ of HK$3.09.
GuruFocus considers 3D Medicines to be Modestly Undervalued.
Key valuation signals for HKSE:01244:
PS Ratio: 1.42 (31% below median its 10-year median of 2.06)
GF Value™: HK$3.09 vs. price of HK$2.27 (26.7% below fair value)
Industry Position: 84.8% below the Biotechnology median (#105 of 940)
No single metric tells the full story. See the HKSE:01244 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
3D Medicines Inc is an investment holding company. The company and its subsidiaries are principally engaged in the research, development and commercialisation of pharmaceutical products.It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China. Its commercialized product is Envita.
47GF Score
Get the complete analysis for HKSE:01244
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:01244 has been successfully added to your 
